Latest News - Aerpio Therapeutics

Thursday, June 29, 2017 | Clinical Trials, Aerpio Therapeutics

Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of AKB-9778 in Patients with DR

Aerpio Pharmaceuticals announced the initiation of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead cand…

Read the full story

Friday, March 17, 2017 | Earnings & Financials, Retina, Aerpio Therapeutics

Aerpio Pharmaceuticals Raises $40 Million

Aerpio Pharmaceuticals, a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced the successful completion of its reverse merger transaction with Aerpi…

Read the full story

Tuesday, June 14, 2016 | Clinical Trials, Aerpio Therapeutics

Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of AKB-9778 in DME: The TIME-2 Trial

Aerpio Therapeutics announced that clinical data from the company’s phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article titl…

Read the full story

Thursday, February 11, 2016 | Clinical Trials, Aerpio Therapeutics

Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study

Aerpio Therapeutics announced promising results in diabetic retinopathy from the company’s phase 2a study (TIME-2) of its lead candidate, AKB-9778, a first-in-class Tie2 activator, according to …

Read the full story